All In Biotech

Drug Trial Radar · NCT04798430

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With HoFH and HeFH, CVD, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction

Last checked: Nov 20, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,000

Planned (sponsor's estimate)

Start

Dec 3, 2020

Primary completion

Jul 30, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
LIB Therapeutics LLCIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Mar 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks with monthly (Q4W \[\<31 days\]) dosing of subcutaneous (SC) LIB003 300 mg administered in patients with CVD or at high risk for CVD (including HoFH and HeFH) on stable diet and oral LDL-C lowering drug therapy who completed one of the LIB003 Phase 3 base studies.

Conditions

  • Cardiovascular Disease With Mention of Arteriosclerosis
  • Elevated Cholesterol
  • Familial Hypercholesterolemia

Interventions

  • lerodalcibepDrug

    PCSK9 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory Activities as severe, moderate or mild after 48 and 72 weeksTime frame: 72 weeks

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • NorthShore University Health System

    Evanston, Illinois

  • Sterling Research Group

    Cincinnati, Ohio

  • The Lindner Research Center

    Cincinnati, Ohio

  • Metabolic & Atherosclerosis Research Center (MARC)

    Cincinnati, Ohio

  • G.B. Pant Institute of Postgraduate Medical Education & Research

    New Delhi, India

  • Department of Medicine, Hadassah University Hospital

    Jerusalem, Israel

  • Rabin Medical Center, Beilinson Hospital,

    Petah Tikva, Israel

  • Lipid Clinic, Oslo University Hospital

    Oslo, Norway

  • Carbohydrate and Lipid Metabolism Research Unit

    Johannesburg, Gauteng, South Africa

  • Division of Lipidology, Department of Medicine University of Cape Town

    Cape Town, Western Province, South Africa

  • Afyonkarahisar Health Sciences University

    Afyonkarahisar, Turkey (Türkiye)

  • Ege University Medical School

    Izmir, Bornova, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.